An email will be sent from ¶¶Òõpro's eIRB system letting you know when the study has been approved. IRB approval is documented by a full approval letter, which is accessed in the eIRB system.
Do not start your research project until the approval letter has been issued and all other applicable institutional or hospital approvals are in place.
Importantly, researchers are expected to carry out their research in accordance with the procedures and using the materials, approved by the IRB. Any deviations will require approval by the IRB prior to implementation of the change.
This page contains information on IRB expectations for conducting IRB-approved research and the forms and guidance you may need along the way.
¶¶Òõpro investigators are responsible for conducting research in an ethical and professional manner, and in accordance with federal regulations (both the general regulations pertaining to human subjects protection in 45 CFR 46 and 21 CFR 50 and 56, and any specific regulations that may be imposed by the federal agency funding the research), local, state, and federal laws, ¶¶Òõpro policies, and the IRB-approved protocol.
Any non-compliance must be promptly reported to the IRB.
The principal investigator (PI) is also responsible for the timely and proper administration of the research project. Beyond the scientific and clinical conduct of the study, responsibilities include:
- Fiscal management of the project
- Training and supervision of research team members
- Compliance with the sponsor’s terms and conditions (e.g., non-disclosure of sponsor confidential information)
- Submission of study amendments and continuing review applications in a timely manner
- Obtaining approval for protocol changes prior to implementation
- Timely submission of post-approval reporting requirements
- Disclosure of any potential conflicts of interest (for self and research team members)*
* Disclosures of potential conflicts of interest are reviewed and managed by institutional COI committees or designees; however, the IRB has the final authority to decide whether the potential conflict of interest and its management, if any, allows the research to be approved.
Please be aware of post-IRB approval submission requirements for more information on the types of events, when to submit, and the appropriate form to use. The following activities require further submission to the IRB. Submissions should be done in eIRB; for paper SLU IRB studies, links to paper forms are below.
Amendments
Modifications to the approved research may not be implemented without prior IRB review
and approval, except when necessary to eliminate immediate hazards to research participants.
Modifications include revisions to any protocol, research procedure, recruitment plan,
study instrument, research personnel, study site, or related study document.
For studies not in eIRB: Change-in-Protocol/For Information Form.
Continuing Review
IRB review is required at least annually for all non-exempt research unless a shorter
approval period was determined by the IRB. The purpose of continuing review is to
monitor the progress of the study and ensure that it continues to meet the requirements
for approval. It is the principal investigator's responsibility to complete the continuing
review form in a timely manner or study approval may expire.
For studies not in eIRB: Continuing Review Form/Notice of Study Closure.
Reportable Events
Serious adverse events, unanticipated problems, protocol violations, complaints and
other events must be reported as detailed in the IRB Reportable Events Guidelines.
For studies not in eIRB: Change-in-Protocol/For Information Form or Serious Adverse Event (SAE) Report Form.
- Decision Tree for Reporting Protocol Violations (PVs)
- Decision Tree for Reporting Serious Adverse Events (SAEs)
- Decision Tree for Reporting Unanticipated Problems (UPs)
Study Closure
If all research-related interventions or interactions with human subjects have been
completed and all data collection and analysis of identifiable private information
described in the IRB-approved protocol has been finished, the human subjects research
study has been completed and the investigator should close the study. Studies should
be closed in accordance with the SLU IRB Guidelines for Closure of Human Subjects Research Studies. Please note record retention requirements specified in that guidance.
For studies not in eIRB: Continuing Review Form/Notice of Study Closure.
When faculty leave/are no longer SLU employees, they/their department are expected to close their study(ies), transfer the protocol(s) to another SLU investigator, or transfer them to their new institution. There have been exceptions made for Emeritus faculty, who can keep their protocols active with Dept Chair approval. Read our Guidelines for Closure of Human Subjects Research Studies for more information.
If terminating employment/association with SLU, PI should do one of the following:
- Close the study at SLU and submit a Final Report Form in eIRB; OR
- Transfer the protocol to another SLU investigator via an Amendment; OR
- Request transfer of research outside of SLU.
Note: Research records must remain at SLU unless otherwise authorized in an agreement. See the SLU Policy on Research Records and Biological Specimens: Ownership, Retention, Transfer, and Destruction.
Industry-sponsored studies often are run with organizational binders provided by the study’s sponsor/CRO. For investigator-initiated studies, researchers can refer to the Regulatory Binder Guidance to put an organizational system in place. In addition, SLU provides some sample logs, though units are welcome to develop their own.